Mechano-energetic uncoupling in hypertrophic cardiomyopathy: Pathophysiological mechanisms and therapeutic

Vasco Sequeira1, Mark T Waddingham2, Hirotsugu Tsuchimochi2

  • 1DZHI, Department of Translational Science Universitätsklinikum, Würzburg, Germany.

Insights

Hypertrophic cardiomyopathy (HCM) involves heart muscle thickening due to genetic and non-genetic factors. This study highlights hypercontractility and energy metabolism changes as key drivers of HCM progression to heart failure and sudden cardiac death.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Hypertrophic cardiomyopathy (HCM) is a common inherited heart failure.
  • Mutations in sarcomeric protein genes are primary causes, but non-genetic factors also contribute.
  • Disease progression involves diastolic dysfunction and hypertrophic remodeling.

Purpose of the Study:

  • To explore the role of hypercontractility in HCM pathogenesis.
  • To investigate cellular energy alterations in HCM progression.
  • To link these mechanisms to heart failure and sudden cardiac death in HCM.

Main Methods:

  • Review of experimental and clinical studies.
  • Analysis of genetic and non-genetic factors in HCM.
  • Investigation of cellular energy metabolism and signaling pathways.

Main Results:

  • Hypercontractility is central to HCM, leading to increased mitochondrial workload and oxidative stress.
  • Energy depletion and mechano-energetic uncoupling drive cardiac growth via signaling pathways.
  • Metabolic remodeling includes reduced fatty acid oxidation and increased glucose uptake; ketones may offer protective effects.

Conclusions:

  • Hypercontractility and cellular energy deficits are critical in HCM progression.
  • Understanding these mechanisms is vital for developing effective therapeutic strategies for HCM.
  • Targeting metabolic pathways and energy balance may offer new treatment avenues for HCM patients.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
525